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Abstract
Background—Alcohol is a recognized risk factor for invasive breast cancer, but few studies 
involve African American women.
Methods—The present analysis included 22,338 women (5,108 cases of invasive breast cancer) 
from the African American Breast Cancer Epidemiology and Risk (AMBER) Consortium. The 
association between number of alcoholic drinks per week (dpw) and breast cancer was estimated 
using logistic regression, adjusting for potential confounders, and stratifying by breast cancer 
subtype.
Results—Approximately 35% of controls were current drinkers at interview. Women who 
reported current drinking of ≥14 dpw had an elevated risk of breast cancer compared to light 
drinkers (>0–<4 dpw) [adjusted odds ratio (adjOR), 95% confidence interval (CI): 1.33 (1.07–
1.64)]. We observed elevated risk among women drinking ≥7 dpw for ER− [adjOR, 95% CI: 1.31 
(1.00–1.72)], PR− [adjOR, 95% CI: 1.28 (1.00–1.63)], HER2− [adjOR, 95% CI: 1.36 (1.09–
1.70)], and triple negative [adjOR, 95% CI: 1.39 (0.98–2.00)] molecular subtype. Among receptor-
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positive cases, ORs remained elevated but attenuated relative to receptor-negative cases. 
Sensitivity analysis of age-defined windows of exposure (<30 years, 30–49, 50+ years of age) did 
not reveal variation in patterns of association. Risk associated with alcohol intake did not vary 
significantly by oral contraceptive use, smoking status, or menopausal status.
Conclusions—Among African American women, similar to women of European descent, 
drinking ≥7 alcoholic dpw was associated with an increased risk of breast cancer regardless of 
subtype.
Impact—Alcohol intake is a modifiable risk factor for breast cancer and reduced intake among 
African American women should be encouraged.
INTRODUCTION
Although alcohol is an established risk factor for breast cancer, most studies have been 
conducted in predominantly white populations (1–9). African Americans report less alcohol 
intake than whites for a variety of reasons including religious beliefs and prevalence of 
comorbid conditions, such as type 2 diabetes or hypertension (10–18). Furthermore, African 
American women have different patterns of exposure to other breast cancer risk factors, 
including parity, oral contraceptive use, age at menarche, breastfeeding, and age at first birth 
(11,13,19–21). Many risk factors, including alcohol exposure, contribute to breast cancer 
development by altering duration of exposure or activity of hormones (22,23). Thus, it is 
important to understand the relationship between alcohol and breast cancer risk in context of 
other exposures.
Many breast cancer risk factors have distinct effects on risk of ER-positive versus ER-
negative breast cancers (21,24,25), and several studies have shown distinct risk factor 
profiles for triple-negative breast cancers (26–31). Despite suggestions that alcohol exposure 
may modulate estrogen metabolism pathways (32), there has been limited evidence that 
alcohol exposure produces distinct effects on risk of ER-positive vs. ER-negative breast 
cancer. Moreover, very few studies have evaluated alcohol-associated risk of triple-negative 
breast cancers (1,14). Alcohol is hypothesized to be a ‘complete carcinogen’ acting as both 
an initiator and promoter of the disease through inhibition of DNA synthesis and repair (33–
36). The current study used data from the African American Breast Cancer Epidemiology 
and Risk (AMBER) consortium to examine alcohol drinking among African American 
women as a risk factor for invasive breast cancer overall, by hormone receptor status, and 
triple negative subtype. Both recent and age-defined periods of alcohol exposure were 
evaluated in association with risk.
MATERIALS AND METHODS
Study population
This analysis included 22,338 African American women from the African American Breast 
Cancer Epidemiology and Risk (AMBER) consortium of four large epidemiologic studies of 
breast cancer. The parent studies include the Carolina Breast Cancer Study (CBCS) (37), the 
Black Women’s Health Study (BWHS) (38), the Multiethnic Cohort Study (MEC) (39) and 
the Women’s Circle of Health Study (WCHS) (40). The study details for the AMBER 
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consortium have been previously described (41). Briefly, CBCS Phases 1 and 2 is a 
population-based case-control study conducted in North Carolina from 1993–2001. Breast 
cancer cases were identified through rapid case ascertainment in cooperation with the NC 
Central Cancer Registry. Controls were selected from North Carolina Department of Motor 
Vehicles (women aged 20 to 64) and Health Care Administration Financing lists (women 
aged 65 to 74). BWHS is a prospective cohort study of 59,000 African American women 
from around the United States enrolled by mailed questionnaire starting in 1995 with follow-
up questionnaires administered every other year. Cases were identified by self-report and 
confirmed by medical record review or linkage with state cancer registries. MEC is a 
prospective cohort study based in Hawaii and Los Angeles, California, consisting of women 
from five different racial-ethnic groups with over 16,000 African American women enrolled 
from 1993–1996. Cases were identified via linkage to the Los Angeles County Cancer 
Surveillance Program, the State of California Cancer Registry, and the Hawaii State Cancer 
Registry. WCHS is a case-control study started in 2002 in New York City hospitals and 
expanded into ten counties in New Jersey, with cases identified by rapid case ascertainment 
by the New Jersey State Cancer Registry. Controls were identified by Random Digit Dialing 
in both sites, complemented in NJ with community-based recruitment (42). MEC and 
BWHS are prospective cohort studies sampled as nested case-control studies with cases and 
controls frequency matched by 5-year age categories, geographic location, and most recent 
questionnaire completed (43). Research protocols for each study were approved by the 
Institutional Review Board at the respective institutions. All subjects provided informed 
consent for study enrollment.
Eligible cases were women with a first diagnosis of invasive breast cancer (N=5,108). Tumor 
subtype for Estrogen Receptor (ER), Progesterone Receptor (PR) and Human Epidermal 
Growth Factor Receptor 2 (HER2) classification was based on pathology data from hospital 
records or cancer registry records. Cases were classified as ER+ or PR+ if marker expression 
was recorded as positive or borderline in the clinical record. ER and PR status was missing 
for approximately 25% of cases in the AMBER consortium (24). HER2 negative status was 
defined as immunohistochemistry (IHC) reported as 0 or 1+ staining intensity or a 
combination of negative by fluorescence in situ hybridization and 2+ by IHC. HER2 testing 
was not routine until the mid-2000’s and is missing for approximately 50% of AMBER 
cases (24). Triple negative cases were classified as negative for ER, PR and HER2.
Exposure Assessment
Each study ascertained alcohol intake via study questionnaire. For CBCS, type of alcohol 
(beer, wine, liquor) and amount (drinks per day, week, month) was queried for the following 
age ranges for each participant: <25, 25 to 49, and ≥50. WCHS collected alcoholic 
drinks/day for each decade of life. For BWHS, type of alcohol (beer, wine, liquor) and 
amount (drinks per day, week, month) was asked at baseline and amount was reported on the 
follow-up survey administered every other year. For MEC, alcohol intake data was gathered 
at baseline in 1993, and on the follow-up questionnaire in 2003. Participants reported the 
number of days per week they drank alcohol and how many glasses/cans/bottles/drinks of 
beer/wine/liquor they consumed. Level of recent alcohol intake was determined by the self-
reported drinking in the age category that included diagnosis age (for cases) or enrollment 
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age (for non-cases) for all studies. Forty-four cases (0.8%) and 256 controls (1.5%) were 
excluded from all analyses due to missing information on alcohol drinking.
Statistical Analyses
Participants were coded as never, past, or current drinkers based on recent use. To be 
classified as a never drinker, participants had to report never drinker for each of the surveys 
preceding their index date. To be a past drinker, participants had to report drinking during a 
time period before the period most proximal to the index date and report no alcohol intake in 
the period most proximal to diagnosis. Exposure categories (drinks/week) for analyses 
stratified by subtype and modifiers were: never drinkers, past drinkers, >0 to <4 (referent), 
≥4 to <7, and ≥7. The highest exposure category for stratified analyses was chosen because 
seven or more drinks exceeds the Dietary Guidelines for Americans as determined by Health 
and Human Services recommending no more than 1 drink a day for women. Further, a 
relatively small number of women in the study exceeded 7 drinks/week, so stratified 
analyses resulted in too few women in the highest category to produce reliable estimates. For 
the main analysis (overall invasive breast cancer risk), the highest category was divided into 
two: ≥7–<14 and ≥14 drinks/week. The referent category, light drinking (>0 to <4 drinks/
week), was selected using flexible modeling techniques with drinks/week modeled as a 
squared-term and graphed against the log odds of breast cancer with the corresponding 95% 
confidence intervals (Supplemental Figure 1).
To examine critical exposure windows for alcohol intake, we created 3 age categories to 
describe intake during the following time periods: young adult (age <25 for CBCS, <30 for 
WCHS), middle adult (age 25–49 for CBCS, and 30–49 WCHS), and older adult (age 50 
and older). Since WCHS asked about intake for each decade, the number of drinks/week for 
<20 and 20–29 was averaged to obtain the number of drinks/week for <30 years of age. This 
same rule was applied for 30–49 years of age (averaging the thirties and forties), and 50 
years of age or greater (averaging the fifties and subsequent decades prior to diagnosis). The 
following alcohol intake categories (drinks/week) were used: 0, >0 to <4 (referent), ≥4 to 
<7, and ≥7.
Logistic regression was used to calculate the odds ratio (OR) and 95% confidence interval 
(95% CI) for alcohol drinking and breast cancer risk. Two-sided p-values and a significance 
level of 0.05 were used for all tests of statistical significance. To evaluate modification by 
study, duration of oral contraceptive use, smoking status, and menopausal status, likelihood 
ratio tests were conducted comparing the model with the interaction term to a reduced 
model. Covariates selected as confounders in the multivariable (MV) logistic regression 
models were selected based on subject matter knowledge and were used in the construction 
of a directed acyclic graph (44). Covariates were coded as follows: study time period (1993–
1998, 1999–2005, 2006–2013), United States geographic location of the participant 
(Northeast, South, Midwest, and West), parent study, age at diagnosis for cases or age at 
index date for controls (less than 40, 40–49, 50–59, 60–69, 70 or older), level of education 
(<12 years, 12 years, 13–15 years, 16 years, >16 years), age at menarche (<11 years, 11–12, 
13–14, 15–16, 17 or older), parity (nulliparous, 1, 2, 3, or 4 or more live births), 
postmenopausal hormone therapy (HT) use defined as duration of combined estrogen and 
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progesterone use (never used, ever used), recent body mass index (BMI). Smoking status 
(never, former, current smoker), duration of oral contraceptive use (never, 1–9 years, 10 or 
more years) and menopausal status (pre-, post-) were considered as possible effect 
modifiers, but ultimately added as adjustment variables in unstratified MV models. A 
complete case analysis was used for the basic and MV logistic models (resulting in 
exclusion of approximately 15% percent of cases and controls in the MV model, largely due 
to missing menopausal status). Analyses among excluded participants produced similar 
estimates to those from MV models presented. Tests for trend for drinks/week were 
conducted using >0 to <4 (referent), ≥4 to <7, ≥7–<14 and ≥14 where noted, and excluded 
never/past drinkers. Alcohol categories were treated as an ordinal variable with the beta 
coefficient p-value serving as the measure of significance for the test of linear trend. All 
analyses were done in SAS version 9.3 (SAS Institute, Cary, NC).
RESULTS
The present analysis includes 5,108 cases of invasive breast cancer and 17, 230 controls. 
Forty-five percent of participants were never drinkers and 20.8% were past drinkers. Recent 
drinking patterns differed by study (Table 1). Approximately 11% of cases and controls 
reported drinking ≥4 drinks/week. CBCS, BWHS and MEC had higher proportions of 
current drinkers (CBCS: 40.6% of cases, 42.1% of controls; BWHS: 35.4% of cases, 37.8% 
of controls; MEC: 35.1% of cases, 34.5% of controls) than WCHS (16.9% of cases, 17.5% 
of controls). Additional participant characteristics overall and by study can be found in 
Supplemental Table 1.
Case-control odds ratios (OR) and 95% confidence intervals (95% CI) for the overall 
association between alcohol intake and breast cancer are presented in Table 2. Odds ratios 
for a minimally adjusted basic model and a multivariable (MV) model (adjusted ORs) are 
reported in the tables. We observed a J-shaped curve between recent alcohol intake 
categories (excluding past drinking) and risk of invasive breast cancer. Compared to light 
drinkers, overall, never drinking was associated with elevated risk of breast cancer [adjusted 
OR 1.12, 95% CI (1.02–1.24), Table 2]. Drinking ≥14 drinks/week was associated with 
significantly increased risk of invasive breast cancer [adjusted OR 1.33, 95% CI (1.07–1.64), 
Table 2]. When analyses were stratified by hormone receptor (HR) status, elevated risk was 
observed in the highest intake category for all subtypes. Table 2 shows slightly stronger risk 
associated with ≥7 drinks/week among ER negative [adjusted OR: 1.31, 95% CI (1.00–
1.72)], PR negative [adjusted OR: 1.28, 95% CI (1.00–1.63)], HER2 negative [adjusted OR: 
1.36, 95% CI (1.09–1.70)], and triple negative cases [adjusted OR: 1.39, 95% CI (0.98–
2.00)]. Associations were in the same direction for ER+, PR+, and HER2+ breast cancers, 
but were slightly attenuated and non-significant.
Among the four studies, CBCS had the strongest J-shaped pattern of risk: compared to 
drinking >0–<4 drinks/week, the adjusted ORs were [1.23, 95% CI (0.92–1.65)], [1.50, 95% 
CI (1.11–2.03)], and [2.03, 95% CI (1.29–3.18)], respectively, for never drinking, past 
drinking, and drinking ≥7 drinks/week (Table 3). There were no associations between risk of 
breast cancer and any alcohol intake in WCHS. In BWHS and MEC, associations between 
alcohol intake and risk were similar in direction to those in CBCS, but lower in magnitude 
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(Table 3). BWHS never drinkers had a significantly elevated risk of breast cancer [adjusted 
OR 1.17, 95% CI (1.02–1.34)]. The multivariable p-value for heterogeneity was 0.10.
We evaluated effect modification by smoking status, duration of oral contraceptive use, and 
menopausal status (Supplemental Table 2, Supplemental Table 3, and Supplemental Table 4, 
respectively). We did not observe evidence for statistical interaction between alcohol intake 
and smoking status in the multivariable model (MV p=0.58, Supplemental Table 2). Risk 
was elevated in the highest alcohol intake category across all strata of smoking status. 
Similarly, we did not observe evidence of statistical interaction for alcohol intake and 
duration of oral contraceptive use (MV p=0.17, Supplemental Table 3) or menopausal status 
(MV p=0.38, Supplemental Table 4).
We evaluated drinking during specific age-defined periods. Associations between recent 
drinking and risk were attenuated when alcohol drinking was assessed by age-at-exposure, 
but only two of the four AMBER studies (CBCS and WCHS) had data available for drinking 
at different time periods so sample size is limited. ORs for early, middle, and later life were 
close to the null and did not show the dose-response trend observed for recent drinking 
(Table 4).
DISCUSSION
In this study among African American women in the AMBER consortium, we found 
evidence of a J-shaped curve for alcohol drinking and invasive breast cancer risk. Women 
who reported drinking 14 or more drinks/week as compared to those drinking >0 – <4 
drinks/week experienced the highest risk of invasive breast cancer. Never drinkers also 
experienced a significantly elevated risk of breast cancer. The J-shaped curve was not 
substantially altered when stratifying by hormone receptor status or triple negative subtype. 
In subtype-stratified analyses, alcohol intake of 7 or more drinks/week was associated with 
increased risk of breast cancer across all subtypes studied. There was no evidence for 
statistical interaction by smoking, oral contraceptive use, or menopausal status. Interestingly, 
past drinkers were most often found to have a lower risk of breast cancer than women 
reporting recent use, suggesting that decreasing alcohol consumption may reduce risk. We 
conclude that alcohol is a risk factor for invasive breast cancer among African American 
women, as has been consistently shown among studies primarily involving white women.
Previous studies of alcohol and cancer have found J-shaped curves similar to those observed 
in this study (6,45), but few breast cancer studies have assessed or reported this dose-
response pattern (3–8,11,46–48). We hypothesize that J-shaped curve morphology may be 
attributable in part to women with unmeasured comorbidities that preclude alcohol drinking, 
yet contribute to increased risk of breast cancer among never drinkers, such as type 2 
diabetes (6,49). A behavioral study found that as self-reported health status moves from poor 
to excellent among African American women, there is a 10% increase in the odds of alcohol 
drinking (16). In our study, women who were never drinkers were more frequently of obese 
BMI, had lower education (with the exception of BWHS), and were more likely report never 
having a mammogram. Future studies that explicitly capture comorbidities and reasons for 
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abstaining from alcohol would help to elucidate the reasons for our observed elevated risk in 
never drinkers.
Our findings of elevated risk among women drinking 14 or more drinks/week are consistent 
with two large meta-analyses and other epidemiologic studies conducted among primarily 
white women (3–8,11,46,47). Our findings are also consistent with the literature showing an 
increased risk of both HR+ and HR- subtypes with increasing alcohol intake (3,8,47,50–54). 
Considering other co-exposures, similar to our findings, smoking did not modify alcohol-
associated risk in a meta-analysis of 53 epidemiologic studies and a separate pooled analysis 
where elevated risk was seen in the highest intake category of alcohol intake regardless of 
smoking status (5,53). The patterns of risk for duration of oral contraceptive use mirrored 
those of our overall risk estimates, with a J-shaped curve and no evidence of statistical 
interaction, consistent with previous findings (2,14).
The most important difference between our findings and previous literature was with regard 
to menopausal status and age-related patterns. We observed no differences in associations by 
menopausal status; previous studies among white women have suggested that 
postmenopausal women who consumed alcohol were at an elevated risk of breast cancer 
compared to premenopausal women (3,8,48,51,53). However, our menopause findings are 
echoed in our analysis of risk by age-period. Previous studies have suggested that drinking 
prior to 40–50 years of age has a greater impact on breast cancer risk relative to drinking at 
older ages (8,51) These previous studies have been conducted predominantly in white 
women, and different patterns of co-exposures such as reproductive behavior may underlie 
inconsistencies.
Our study has some limitations. First, we did not have dietary intake or complete physical 
activity information for all the studies in the AMBER consortium and did not account for 
these covariates in our analyses. Additionally, we did not have information on reasons for 
alcohol abstinence, which could shed light on the elevated risk observed among never 
drinkers in our study. Our pooled analysis approach may be affected by differences between 
studies. Differences in categorical data collection between studies prevented evaluation of 
intake as a continuous variable, by grams of alcohol or by alcohol type, but previous studies 
suggest that cancer risk is most strongly associated with the type of alcoholic beverage most 
frequently consumed in a population (3,6). Furthermore, while we did not find statistical 
evidence of heterogeneity by study, we did observe some study-specific qualitative 
differences in the alcohol-risk association. Finally, case-control studies in the consortium 
may have been subject to recall bias, but work from the Nurses’ Health Study did not find 
significant differences in recall of alcohol intake comparing pre- and post-diagnosis 
questionnaires among women with breast cancer (55).
To conclude, in a large consortium of African American women from around the United 
States, risk of breast cancer was elevated among never drinkers as well as those who 
reported drinking 7 or more drinks/week, irrespective of HR status or triple negative 
subtype. Our findings support alcohol as a risk factor for breast cancer in African American 
women, where risk associations have been less well-studied. Future work should seek to 
understand why African American women who abstain from alcohol have an increased risk 
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of breast cancer. Finally, our results suggest that drinking cessation may be associated with a 
reduced risk of invasive breast cancer and may be a targetable public health intervention 
strategy among African American women.
Supplementary Material
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Acknowledgments
Funding Sources: This work was supported by the National Institutes of Health: P01 CA151135 (C.B. Ambrosone, 
J.R. Palmer, and A.F. Olshan), R01 CA058420 (L. Rosenberg), UM1 CA164974 (L. Rosenberg and J.R. Palmer), 
R01 CA098663 (J.R. Palmer), R01 CA100598 (C.B. Ambrosone), UM1 CA164973 (L.N. Kolonel), R01 CA54281 
(L.N. Kolonel), P50 CA58223 (M.A. Troester and A.F. Olshan), U01 CA179715 (M.A. Troester and A.F. Olshan); 
and by the Komen for the Cure Foundation, the Breast Cancer Research Foundation (C.B. Ambrosone); and the 
University Cancer Research Fund of North Carolina. The results do not necessarily reflect the views of the NIH or 
the sponsors, who had no role in study design; data collection, analysis, or interpretation; or writing and submission 
of the manuscript.
References
1. Kabat GC, Kim M, Phipps AI, Li CI, Catherine R, Wactawski-wende J, et al. Smoking and alcohol 
consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal 
women. Cancer causes & control: CCC. 2012; 22:775–83.
2. Dumeaux V, Lund E, Hjarta A. Use of Oral Contraceptives, Alcohol, and Risk for Invasive Breast 
Cancer. Cancer Epidemiology, Biomarkers & Prevention. 2004; 13:1302–7.
3. Fagherazzi G, Vilier A, Boutron-Ruault M-C, Mesrine S, Clavel-Chapelon F. Alcohol consumption 
and breast cancer risk subtypes in the E3N-EPIC cohort. European journal of cancer prevention: the 
official journal of the European Cancer Prevention Organisation (ECP). 2014:1–6. [PubMed: 
23492954] 
4. Tjønneland A, Christensen J, Olsen A, Stripp C, Thomsen BL, Overvad K, et al. Alcohol intake and 
breast cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer 
causes & control: CCC. 2007; 18:361–73. [PubMed: 17364225] 
5. Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW, et al. Alcohol, tobacco and breast 
cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 
58,515 women with breast cancer and 95,067 women without the disease. British journal of cancer. 
2002; 87:1234–45. [PubMed: 12439712] 
6. Allen NE, Beral V, Casabonne D, Kan SW, Reeves GK, Brown A, et al. Moderate alcohol intake and 
cancer incidence in women. Journal of the National Cancer Institute. 2009; 101:296–305. [PubMed: 
19244173] 
7. Longnecker MP, Berlin JA, Orza MJ, Chalmers TC. A Meta-analysis of Alcohol Consumption in 
Relation to Risk of Breast Cancer. JAMA: the journal of the American Medical Association. 1988; 
260:652–6. [PubMed: 3392790] 
8. Terry MB, Zhang FF, Kabat G, Britton Ja, Teitelbaum SL, Neugut AI, et al. Lifetime alcohol intake 
and breast cancer risk. Annals of epidemiology. 2006; 16:230–40. [PubMed: 16230024] 
9. Park SY, Kolonel LN, Lim U, White KK, Henderson BE, Wilkens LR. Alcohol consumption and 
breast cancer risk among women from five ethnic groups with light to moderate intakes: The 
Multiethnic Cohort Study. International Journal of Cancer. 2014; 134:1504–10. [PubMed: 
24037751] 
10. Volcik, Ka, Ballantyne, CM., Fuchs, FD., Sharrett, aR, Boerwinkle, E. Relationship of alcohol 
consumption and type of alcoholic beverage consumed with plasma lipid levels: differences 
between Whites and African Americans of the ARIC study. Annals of epidemiology. 2008; 
18:101–7. [PubMed: 17855114] 
Williams et al. Page 8
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
11. Kinney, aY, Millikan, RC., Lin, YH., Moorman, PG., Newman, B. Alcohol consumption and breast 
cancer among black and white women in North Carolina (United States). Cancer causes & control: 
CCC. 2000; 11:345–57. [PubMed: 10843445] 
12. Jackson CL, Hu FB, Kawachi I, Williams DR, Mukamal KJ, Rimm EB. Black–White Differences 
in the Relationship Between Alcohol Drinking Patterns and Mortality Among US Men and 
Women. American Journal of Public Health. 2015; 105:S534–43. [PubMed: 25905819] 
13. Darrow SL, Russell M, Cooper ML, Mudar PJ, Frone M. Sociodemographic Correlates of Alcohol 
Consumption Among African-American and White Women. Women & Health. 1992; 18:1–15.
14. Williams, LA., Olshan, AF., Tse, CK., Bell, ME., Troester, MA. Cancer Causes & Control. Vol. 27. 
Springer International Publishing; Alcohol intake and invasive breast cancer risk by molecular 
subtype and race in the Carolina Breast Cancer Study; p. 259-69.
15. Jones-Webb R. Drinking patterns and problems among African-Americans: recent findings. 
Alcohol health and research world. 1998; 22:260–4. [PubMed: 15706752] 
16. Holt CL, Roth DL, Huang J, Clark EM. Gender Differences in the Roles of Religion and Locus of 
Control on Alcohol Use and Smoking Among African Americans. Journal of Studies on Alcohol 
and Drugs. 2015; 76:482–92. [PubMed: 25978836] 
17. Angelica MD, Fong Y. Ethnicity and Alcohol Consumption among U.S. Adults with Diabetes. Oct.
2008 141:520–9.
18. Zhao G, Ford ES, Mokdad AH. Racial/ethnic variation in hypertension-related lifestyle behaviours 
among US women with self-reported hypertension. Journal of human hypertension. 2008; 22:608–
16. [PubMed: 18496555] 
19. Bernstein L, Teal CR, Joslyn S, Wilson J. Ethnicity-related variation in breast cancer risk factors. 
Cancer. 2003; 97:222–9. [PubMed: 12491485] 
20. Hall IJ, Moorman PG, Millikan RC, Newman B. Comparative analysis of breast cancer risk factors 
among African-American women and white women. American Journal of Epidemiology. 2005; 
161:40–51. [PubMed: 15615914] 
21. Warner ET, Tamimi RM, Boggs Da, Rosner B, Rosenberg L, Colditz Ga, et al. Estrogen receptor 
positive tumors: do reproductive factors explain differences in incidence between black and white 
women? Cancer causes & control: CCC. 2013; 24:731–9. [PubMed: 23380944] 
22. Singletary KW, Gapstur SM. Alcohol and Breast Cancer: Review of Epidemiologic and 
Experimental Evidence and Potential Mechanisms. JAMA: the journal of the American Medical 
Association. 2001; 286:2143–51. [PubMed: 11694156] 
23. Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nature reviews 
Cancer. 2007; 7:599–612. [PubMed: 17646865] 
24. Ambrosone CB, Zirpoli G, Hong C-C, Yao S, Troester Ma, Bandera EV, et al. Important Role of 
Menarche in Development of Estrogen Receptor-Negative Breast Cancer in African American 
Women. J Natl Cancer Inst. 2015; 107:djv172–djv172. [PubMed: 26085483] 
25. Palmer JR, Boggs DA, Wise LA, Ambrosone CB, Adams-Campbell LL, Rosenberg L. Parity and 
Lactation in Relation to Estrogen Receptor Negative Breast Cancer in African American Women. 
Cancer Epidemiology Biomarkers & Prevention. 2011; 20:1883–91.
26. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Wactawski-Wende J, Kuller LH, et al. 
Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. 
Journal of the National Cancer Institute. 2011; 103:470–7. [PubMed: 21346227] 
27. Li CI, Beaber EF, Tang M-TC, Porter PL, Daling JR, Malone KE. Reproductive factors and risk of 
estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among 
women 20–44 years of age. Breast cancer research and treatment. 2013; 137:579–87. [PubMed: 
23224237] 
28. Millikan RC, Newman B, Tse C-K, Moorman PG, Conway K, Dressler LG, et al. Epidemiology of 
basal-like breast cancer. Breast cancer research and treatment. 2008; 109:123–39. [PubMed: 
17578664] 
29. Dolle JM, Daling JR, White E, Brinton La, Doody DR, Porter PL, et al. Risk factors for triple-
negative breast cancer in women under the age of 45 years. Cancer Epidemiology, Biomarkers & 
Prevention. 2009; 18:1157–66.
Williams et al. Page 9
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
30. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, et al. Differences in 
risk factors for breast cancer molecular subtypes in a population-based study. Cancer 
Epidemiology, Biomarkers & Prevention. 2007; 16:439–43.
31. Bandera EV, Chandran U, Hong C-C, Troester Ma, Bethea TN, Adams-Campbell LL, et al. 
Obesity, body fat distribution, and risk of breast cancer subtypes in African American women 
participating in the AMBER Consortium. Breast Cancer Research and Treatment. 2015; 150:655–
66. [PubMed: 25809092] 
32. Eriksson CJ, Fukunaga T, Sarkola T, Lindholm HAL. Estrogen-related acetaldehyde elevation in 
women during alcohol intoxication. Alcoholism, clinical and experimental research. 1996; 
20:1192–5.
33. Beland FA, Benson RW, Mellick PW, Kovatch RM, Roberts DW, Fang JLDD. Effect of ethanol on 
the tumorigenicity of urethane (ethyl carbamate) in B6C3F1 mice. Food and chemical toxicology. 
2005; 43:1–19. [PubMed: 15582191] 
34. Soffritti M, Belpoggi F, Cevolani D, Guarino M, Padovani MMC. Results of long-term 
experimental studies on the carcinogenicity of methyl alcohol and ethyl alcohol in rats. Annals of 
the New York Academy of Sciences. 2002; 982:46–69. [PubMed: 12562628] 
35. Watabiki T, Okii Y, Tokiyasu T, Yoshimura S, Yoshida M, Akane A, Shikata NTA. Long-term 
ethanol consumption in ICR mice causes mammary tumor in females and liver fibrosis in males. 
Alcoholism, clinical and experimental research. 2000; 24:117S–122S.
36. Wang M, McIntee EJ, Cheng G, Shi Y, Villalta PW, Hecht SS. Identification of DNA Adducts of 
Acetaldehyde. Chemical Research in Toxicology. 2000; 13:1149–57. [PubMed: 11087437] 
37. Newman B, Moorman PG, Millikan R, Qaqish BF, Geradts J, Aldrich TE, et al. The Carolina 
Breast Cancer Study: integrating population-based epidemiology and molecular biology. Breast 
cancer research and treatment. 1995; 35:51–60. [PubMed: 7612904] 
38. Rosenberg L, Adams-Campbell L, Palmer JR. The Black Women’s Health Study: a follow-up 
study for causes and preventions of illness. Journal of the American Medical Women’s 
Association. 1972; (50):56–8.
39. Kolonel LN, Henderson BE, Hankin JH, Nomura AM, Wilkens LR, Pike MC, et al. A multiethnic 
cohort in Hawaii and Los Angeles: baseline characteristics. American journal of epidemiology. 
2000; 151:346–57. [PubMed: 10695593] 
40. Ambrosone CB, Ciupak GL, Bandera EV, Jandorf L, Bovbjerg DH, Zirpoli G, et al. Conducting 
Molecular Epidemiological Research in the Age of HIPAA: A Multi-Institutional Case-Control 
Study of Breast Cancer in African-American and European-American Women. Journal of 
oncology. 2009; 2009:871250. [PubMed: 19865486] 
41. Palmer JR, Ambrosone CB, Olshan AF. A collaborative study of the etiology of breast cancer 
subtypes in African American women: the AMBER consortium. Cancer causes & control: CCC. 
2014; 25:309–19. [PubMed: 24343304] 
42. Bandera EV, Chandran U, Zirpoli G, McCann SE, Ciupak G, Ambrosone CB. Rethinking sources 
of representative controls for the conduct of case-control studies in minority populations. BMC 
medical research methodology. 2013; 13:71. [PubMed: 23721229] 
43. Bethea TN, Rosenberg L, Castro-Webb N, Lunetta KL, Sucheston-Campbell LE, Ruiz-Narvaez 
EA, et al. Family History of Cancer in Relation to Breast Cancer Subtypes in African American 
Women. Cancer Epidemiology Biomarkers & Prevention. 2016; 25:366–73.
44. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 
1999; 10:37–48. [PubMed: 9888278] 
45. Bagnardi V, Randi G, Lubin J, Consonni D, Lam TK, Subar AF, et al. Alcohol consumption and 
lung cancer risk in the environment and genetics in lung cancer etiology (EAGLE) study. 
American Journal of Epidemiology. 2010; 171:36–44. [PubMed: 19933698] 
46. Li CI, Chlebowski RT, Freiberg M, Johnson KC, Kuller L, Lane D, et al. Alcohol consumption and 
risk of postmenopausal breast cancer by subtype: the women’s health initiative observational 
study. Journal of the National Cancer Institute. 2010; 102:1422–31. [PubMed: 20733117] 
47. Falk RT, Maas P, Schairer C, Chatterjee N, Mabie JE, Cunningham C, et al. Alcohol and risk of 
breast cancer in postmenopausal women: an analysis of etiological heterogeneity by multiple 
tumor characteristics. American journal of epidemiology. 2014; 180:705–17. [PubMed: 25150269] 
Williams et al. Page 10
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
48. Li CI. Relationship between Established Breast Cancer Risk Factors and Risk of Seven Different 
Histologic Types of Invasive Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. 
2006; 15:946–54.
49. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: A meta-analysis. 
International Journal of Cancer. 2007; 121:856–62. [PubMed: 17397032] 
50. Gapstur SM, Potter JD, Drinkard C, Folsom R. Synergistic effect between alcohol and estrogen 
replacement therapy on risk of breast cancer differs by estrogen / progesterone receptor status in 
the Iowa Women’s Health Study. Cancer Epidemiology, Biomarkers & Prevention. 1995; 4:313–8.
51. Chen W, Rosner B, Hankinson SE, Colditz GA, Willett WC. Moderate Alcohol Consumption 
During Adult Life, Drinking Patterns, and Breast Cancer Risk. Breast Diseases: A Year Book 
Quarterly. 2011; 23:231–2.
52. Suzuki R, Orsini N, Mignone L, Saji S, Wolk A. Alcohol intake and risk of breast cancer defined 
by estrogen and progesterone receptor status--a meta-analysis of epidemiological studies. 
International journal of cancer Journal international du cancer. 2008; 122:1832–41. [PubMed: 
18067133] 
53. Jung S, Wang M, Anderson K, Baglietto L, Bergkvist L, Bernstein L, et al. Alcohol consumption 
and breast cancer risk by estrogen receptor status: in a pooled analysis of 20 studies. International 
journal of epidemiology. 2015:1–13. [PubMed: 25859586] 
54. Schonberg, Ma, Marcantonio, ER., Li, D., Silliman, Ra, Ngo, L., McCarthy, EP. Breast cancer 
among the oldest old: tumor characteristics, treatment choices, and survival. Journal of clinical 
oncology: official journal of the American Society of Clinical Oncology. 2010; 28:2038–45. 
[PubMed: 20308658] 
55. Giovannucci E, Stampfer MJ, Colditz Ga, Manson JE, Rosner Ba, Longnecker MP, et al. Recall 
and selection bias in reporting past alcohol consumption among breast cancer cases. Cancer causes 
& control: CCC. 1993; 4:441–8. [PubMed: 8218876] 
Williams et al. Page 11
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Williams et al. Page 12
Ta
bl
e 
1
Ex
po
su
re
 c
ha
ra
ct
er
ist
ic
s o
f c
as
es
 a
nd
 c
on
tro
ls 
in
 th
e 
A
M
BE
R 
Co
ns
or
tiu
m
 st
ra
tif
ie
d 
by
 st
ud
y:
 re
ce
nt
 a
lc
oh
ol
 in
ta
ke
, 
sm
o
ki
ng
 st
at
us
, o
ra
l c
on
tra
ce
pt
iv
e 
u
se
, 
an
d 
m
en
op
au
sa
l s
ta
tu
s
C
BC
S 
N
 (%
)
W
C
H
S 
N
 (%
)
M
EC
 N
 (%
)
BW
H
S 
N
 (%
)
To
ta
l N
 (%
)
C
as
es
C
on
tr
o
ls
C
as
es
C
on
tr
o
ls
C
as
es
C
on
tr
o
ls
C
as
es
C
on
tr
o
ls
C
as
es
C
on
tr
o
ls
N
um
be
r o
f a
lc
oh
ol
ic
 d
rin
ks
 p
er
 w
ee
k
 
N
ev
er
 d
rin
ke
rs
29
3 
(37
.5)
30
9 
(39
.4)
79
8 
(65
.4)
79
1 
(65
.1)
62
9 
(55
.5)
2,
36
0 
(53
.3)
79
7 
(40
.4)
4,
06
3 
(37
.6)
2,
51
7 
(49
.3)
7,
52
3 
(43
.4)
 
>
0–
<4
19
3 
(24
.7)
23
2 
(29
.6)
11
3 
(9.
3)
11
1 
(9.
1)
22
6 
(19
.9)
90
6 
(20
.5)
49
2 
(24
.9)
2,
86
8 
(26
.6)
1,
02
4 
(20
.1)
4,
11
7 
(23
.9)
 
≥4
–<
7
32
 (4
.1)
44
 (5
.6)
40
 (3
.3)
43
 (3
.5)
43
 (3
.8)
17
4 
(3.
9)
10
9 
(5.
5)
61
5 
(5.
7)
22
4 
(4.
4)
87
6 
(5.
1)
 
≥7
–<
14
46
 (5
.9)
24
 (3
.1)
30
 (2
.5)
38
 (3
.1)
46
 (4
.1)
19
2 
(4.
3)
68
 (3
.5)
35
1 
(3.
3)
19
0 
(3.
7)
60
5 
(3.
5)
 
≥1
4
42
 (5
.4)
30
 (3
.8)
23
 (1
.9)
22
 (1
.8)
83
 (7
.3)
25
9 
(5.
9)
30
 (1
.5)
13
5 
(1.
3)
17
8 
(3.
5)
44
6 
(2.
6)
 
Pa
st
 d
rin
ke
rs
17
5 
(22
.4)
14
5 
(18
.5)
21
6 
(17
.7)
21
1 
(17
.4)
10
7 
(9.
4)
54
0 
(12
.2)
47
7 
(24
.2)
2,
76
7 
(25
.6)
97
5 
(19
.1)
3,
66
3 
(21
.3)
Sm
ok
in
g 
St
at
us
 
N
ev
er
 S
m
ok
er
43
5 
(55
.7)
46
7 
(59
.6)
74
5 
(61
.1)
70
2 
(57
.7)
50
8 
(45
.7)
2,
05
0 
(46
.9)
1,
16
8 
(59
.3)
6,
28
8 
(58
.3)
2,
85
6 
(56
.2)
9,
50
7 
(55
.4)
 
Cu
rre
nt
 S
m
ok
er
13
4 
(17
.2)
15
0 
(19
.1)
19
9 
(16
.3)
24
4 
(20
.1)
21
6 
(19
.4)
80
7 
(18
.5)
34
3 
(17
.4)
1,
97
8 
(18
.3)
89
2 
(17
.6)
3,
17
9 
(18
.5)
 
Fo
rm
er
 S
m
ok
er
21
2 
(27
.1)
16
7 
(21
.3)
27
6 
(22
.6)
27
0 
(22
.2)
38
8 
(34
.9)
1,
51
5 
(34
.7)
46
0 
(23
.3)
2,
52
5 
(23
.4)
1,
33
6 
(26
.3)
4,
47
7 
(26
.1)
 
M
iss
in
g
0
0
0
0
22
59
2
8
24
67
O
ra
l C
on
tra
ce
pt
iv
e 
U
se
 
N
ev
er
,
 
<
1 
ye
ar
38
0 
(48
.7)
38
6 
(49
.4)
58
9 
(48
.6)
59
3 
(49
.1)
68
8 
(63
.1)
2,
78
0 
(66
.1)
82
5 
(41
.8)
4,
83
1 
(44
.7)
2,
48
2 
(49
.1)
8,
59
0 
(55
.6)
 
1–
9 
ye
ar
s
27
6 
(35
.3)
29
5 
(37
.8)
42
2 
(34
.8)
44
1 
(36
.5)
27
9 
(25
.6)
99
4 
(23
.7)
82
0 
(41
.6)
4,
39
8 
(40
.7)
1,
79
7 
(35
.5)
6,
12
8 
(36
.1)
 
10
+y
ea
rs
12
5 
(16
.0)
10
0 
(12
.8)
20
2 
(16
.7)
17
5 
(14
.5)
12
3 
(11
.3)
42
9 
(10
.2)
32
8 
(16
.6)
1,
57
0 
(14
.5)
77
8 
(15
.4)
2,
27
4 
(13
.4)
 
M
iss
in
g
0
3
7
7
44
22
8
0
0
51
23
8
M
en
op
au
sa
l S
ta
tu
s
 
Pr
e-
28
6 
(40
.9)
29
8 
(43
.1)
57
4 
(49
.6)
56
5 
(49
.1)
14
0 
(12
.7)
38
8 
(9.
0)
71
7 
(42
.7)
4,
17
9 
(43
.6)
1,
71
7 
(37
.0)
5,
43
0 
(34
.5)
 
Po
st
-
41
3 
(59
.1)
39
3 
(56
.9)
58
3 
(50
.4)
58
7 
(50
.9)
96
4 
(87
.3)
3,
90
5 
(90
.0)
96
4 
(57
.4)
5,
41
2 
(56
.4)
2,
92
4 
(63
.0)
10
,2
97
 (6
5.5
)
 
M
iss
in
g
82
93
63
64
30
13
8
29
2
1,
20
8
46
7
1,
50
3
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Williams et al. Page 13
Ta
bl
e 
2
R
ec
en
t a
lc
oh
ol
 in
ta
ke
 in
 re
la
tio
n 
to
 H
or
m
on
e 
Re
ce
pt
or
 st
at
us
 a
m
on
g 
in
v
as
iv
e 
br
ea
st 
ca
nc
er
 c
as
es
 in
 th
e 
A
M
BE
R 
Co
ns
or
tiu
m
C
on
tr
o
ls 
N
 (%
)
C
as
es
 N
 (%
)
Ba
sic
 
m
o
de
la
<
r1
>O
R
 
(95
%
 C
I)
C
on
tr
o
ls 
N
 (%
)
C
as
es
 N
 (%
)
M
V
 m
od
el
b
O
R
 (9
5%
 C
I)
C
as
es
 N
 (%
)
Ba
sic
 m
od
el
a
O
R
 (9
5%
 C
I)
C
as
es
 N
 (%
)
M
V
 m
od
el
b
O
R
 (9
5%
 C
I)
D
rin
ks
 p
er
 w
ee
k
A
ll 
In
v
a
siv
e 
Br
ea
st
 C
an
ce
r
 
N
ev
er
 d
rin
ke
rs
7,
51
6 
(43
.7)
2,
51
7 
(49
.3)
1.
12
 (1
.03
–1
.22
)
6,
47
6 
(43
.4)
2,
13
4 
(49
.1)
1.
12
 (1
.02
–1
.24
)
 
>
0–
<4
4,
11
4 
(23
.9)
1,
02
3 
(20
.0)
R
ef
.
3,
53
9 
(23
.7)
86
2 
(19
.8)
R
ef
.
 
≥4
–<
7
87
6 
(5.
1)
22
3 
(4.
4)
0.
99
 (0
.84
–1
.17
)
75
0 
(5.
0)
19
2 
(4.
4)
1.
04
 (0
.86
–1
.25
)
 
≥7
–<
14
60
5 
(3.
5)
19
0 
(3.
7)
1.
13
 (0
.94
–1
.36
)
53
4 
(3.
6)
15
9 
(3.
7)
1.
07
 (0
.88
–1
.32
)
 
≥1
4
44
6 
(2.
6)
17
8 
(3.
5)
1.
34
 (1
.10
–1
.63
)
39
4 
(2.
6)
14
9 
(3.
4)
1.
33
 (1
.07
–1
.64
)
 
Pa
st
 d
rin
ke
rs
3,
66
1 
(21
.3)
97
3 
(19
.1)
1.
01
 (0
.91
–1
.12
)
3,
22
4 
(21
.6)
85
3 
(19
.6)
1.
04
 (0
.93
–1
.17
)
 
p-
tre
nd
*
0.
01
0.
09
D
rin
ks
 p
er
 w
ee
k
ER
+
ER
−
 
N
ev
er
 d
rin
ke
rs
7,
51
6 
(43
.7)
1,
25
9 
(49
.4)
1.
10
 (0
.98
–1
.23
)
6,
47
6 
(43
.4)
1,
07
2 
(48
.9)
1.
13
 (0
.99
–1
.29
)
63
8 
(46
.3)
1.
12
 (0
.96
–1
.30
)
53
6 
(45
.7)
1.
07
 (0
.90
–1
.27
)
 
>
0–
<4
4,
11
4 
(23
.9)
50
8 
(19
.9)
R
ef
.
3,
53
9 
(23
.7)
42
8 
(19
.5)
R
ef
.
29
7 
(21
.5)
R
ef
.
25
4 
(21
.7)
R
ef
.
 
≥4
–<
7
87
6 
(5.
1)
10
9 
(4.
3)
0.
98
 (0
.78
–1
.23
)
75
0 
(5.
0)
98
 (4
.5)
1.
10
 (0
.86
–1
.40
 )
61
 (4
.4)
0.
97
 (0
.72
–1
.31
)
53
 (4
.5)
1.
02
 (0
.74
–1
.41
)
 
≥7
1,
05
1 
(6.
1)
18
9 
(7.
4)
1.
20
 (1
.00
–1
.45
)
92
8 
(6.
2)
16
1 
(7.
3)
1.
20
 (0
.97
–1
.47
)
11
1 
(8.
1)
1.
35
 (1
.06
–1
.72
)
91
 (7
.8)
1.
31
 (1
.00
–1
.72
)
 
Pa
st
 d
rin
ke
rs
3,
66
1 
(21
.3)
48
4 
(19
.0)
0.
99
 (1
.00
–1
.45
)
3,
22
4 
(21
.6)
43
4 
(19
.8)
1.
07
 (0
.92
–1
.24
)
27
2 
(19
.7)
1.
11
 (0
.92
–1
.33
)
23
8 
(20
.3)
1.
11
 (0
.91
–1
.35
)
 
p-
tre
nd
*
0.
12
0.
18
0.
03
0.
08
D
rin
ks
 p
er
 w
ee
k
PR
+
PR
−
 
N
ev
er
 d
rin
ke
rs
7,
51
6 
(43
.7)
1,
00
1 
(49
.5)
1.
12
 (0
.99
–1
.28
)
6,
47
6 
(43
.4)
85
2 
(48
.8)
1.
14
 (0
.98
–1
.32
)
82
5 
(47
.0)
1.
10
 (0
.96
–1
.26
)
68
8 
(46
.6)
1.
07
 (0
.92
–1
.25
)
 
>
0–
<4
4,
11
4 
(23
.9)
39
5 
(19
.5)
R
ef
.
3,
53
9 
(23
.7)
33
6 
(19
.2)
R
ef
.
37
7 
(21
.5)
R
ef
.
31
8 
(21
.5)
R
ef
.
 
≥4
–<
7
87
6 
(5.
1)
77
 (3
.8)
0.
87
 (0
.67
–1
.13
)
75
0 
(5.
0)
72
 (4
.1)
1.
02
 (0
.77
–1
.35
)
82
 (4
.7)
1.
04
 (0
.80
–1
.35
)
70
 (4
.7)
1.
08
 (0
.81
–1
.43
)
 
≥7
1,
05
1 
(6.
1)
14
2 
(7.
0)
1.
18
 (0
.95
–1
.45
)
92
8 
(6.
2)
12
1 
(6.
9)
1.
19
 (0
.95
–1
.50
)
13
8 
(7.
9)
1.
32
 (1
.06
–1
.64
)
11
2 
(7.
6)
1.
28
 (1
.00
–1
.63
)
 
Pa
st
 d
rin
ke
rs
3,
66
1 
(21
.3)
40
6 
(20
.1)
1.
07
 (0
.95
–1
.46
)
3,
22
4 
(21
.6)
36
6 
(21
.0)
1.
14
 (0
.97
–1
.35
)
33
3 
(19
.0)
1.
02
 (0
.87
–1
.20
)
29
0 
(19
.6)
1.
04
 (0
.88
–1
.25
)
 
p-
tre
nd
*
0.
30
0.
29
0.
03
0.
08
D
rin
ks
 p
er
 w
ee
k
H
ER
2+
H
ER
2−
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Williams et al. Page 14
C
on
tr
o
ls 
N
 (%
)
C
as
es
 N
 (%
)
Ba
sic
 
m
o
de
la
<
r1
>O
R
 
(95
%
 C
I)
C
on
tr
o
ls 
N
 (%
)
C
as
es
 N
 (%
)
M
V
 m
od
el
b
O
R
 (9
5%
 C
I)
C
as
es
 N
 (%
)
Ba
sic
 m
od
el
a
O
R
 (9
5%
 C
I)
C
as
es
 N
 (%
)
M
V
 m
od
el
b
O
R
 (9
5%
 C
I)
 
N
ev
er
 d
rin
ke
rs
7,
51
6 
(43
.7)
25
4 
(46
.8)
1.
01
 (0
.80
–1
.28
)
6,
47
6 
(43
.4)
21
2 
(45
.8)
0.
93
 (0
.72
–1
.21
)
1,
00
7 
(46
.9)
1.
01
 (0
.88
–1
.15
)
85
7 
(46
.4)
1.
04
 (0
.90
–1
.21
)
 
>
0–
<4
4,
11
4 
(23
.9)
11
5 
(21
.2)
R
ef
.
3,
53
9 
(23
.7)
10
1 
(21
.8)
R
ef
.
43
6 
(20
.3)
R
ef
.
36
7 
(19
.9)
R
ef
.
 
≥4
–<
7
87
6 
(5.
1)
31
 (5
.7)
1.
21
 (0
.80
–1
.83
)
75
0 
(5.
0)
28
 (6
.0)
1.
34
 (0
.87
–2
.09
)
87
 (4
.1)
0.
91
 (0
.70
–1
.18
)
79
 (4
.3)
1.
04
 (0
.79
–1
.37
)
 
≥7
1,
05
1 
(6.
1)
44
 (8
.1)
1.
33
 (0
.93
–1
.92
)
92
8 
(6.
2)
33
 (7
.1)
1.
17
 (0
.77
–1
.77
)
16
9 
(7.
9)
1.
27
 (1
.03
–1
.56
)
14
9 
(8.
0)
1.
36
 (1
.09
–1
.70
)
 
Pa
st
 d
rin
ke
rs
3,
66
1 
(21
.3)
99
 (1
8.2
)
0.
94
 (0
.72
–1
.25
)
3,
22
4 
(21
.6)
89
 (1
9.2
)
0.
99
 (0
.73
–1
.73
)
45
0 
(20
.9)
1.
08
 (0
.93
–1
.26
)
39
8 
(21
.5)
1.
15
 (0
.99
–1
.37
)
 
p-
tre
nd
*
0.
06
0.
38
0.
05
0.
01
D
rin
ks
 p
er
 w
ee
k
N
on
 T
ri
pl
e 
N
eg
at
iv
e
Tr
ip
le
 N
eg
at
iv
e
 
N
ev
er
 d
rin
ke
rs
7,
51
6 
(43
.7)
2,
19
5 
(50
.3)
1.
14
 (1
.04
–1
.25
)
6,
47
6 
(43
.4)
1,
86
7 
(50
.1)
1.
14
 (1
.03
–1
.26
)
32
2 
(43
.4)
0.
97
 (0
.77
–1
.20
)
26
7 
(42
.7)
0.
96
 (0
.76
–1
.22
)
 
>
0–
<4
4,
11
4 
(23
.9)
85
9 
(19
.7)
R
ef
.
3,
53
9 
(23
.7)
72
5 
(19
.5)
R
ef
.
16
4 
(22
.1)
R
ef
.
13
7 
(21
.9)
R
ef
.
 
≥4
–<
7
87
6 
(5.
1)
18
8 
(4.
3)
0.
99
 (0
.82
–1
.18
)
75
0 
(5.
0)
16
1 
(4.
3)
1.
02
 (0
.84
–1
.24
)
35
 (4
.7)
1.
01
 (0
.68
–1
.51
)
31
 (5
.0)
1.
14
 (0
.74
–1
.74
)
 
≥7
1,
05
1 
(6.
1)
30
5 
(7.
0)
1.
21
 (1
.04
–1
.40
)
92
8 
(6.
2)
25
5 
(6.
9)
1.
16
 (0
.98
–1
.37
)
63
 (8
.5)
1.
39
 (1
.01
–1
.92
)
53
 (8
.5)
1.
39
 (0
.98
–2
.00
)
 
Pa
st
 d
rin
ke
rs
3,
66
1 
(21
.3)
81
5 
(18
.7)
0.
99
 (0
.89
–1
.11
)
3,
22
4 
(21
.6)
71
6 
(19
.2)
1.
02
 (0
.91
–1
.15
)
15
8 
(21
.3)
1.
19
 (0
.93
–1
.50
)
13
7 
(21
.9)
1.
21
 (0
.93
–1
.58
)
 
p-
tre
nd
*
0.
04
0.
18
0.
06
0.
06
a B
as
ic
 m
od
el
 a
dju
ste
d f
or 
ag
e, 
stu
dy
,
 
tim
e 
pe
rio
d 
an
d 
ge
og
ra
ph
ic
 re
gi
on
.
b M
ul
tiv
ar
ia
bl
e 
m
od
el
 a
dju
ste
d f
or 
ag
e, 
stu
dy
,
 
tim
e 
pe
rio
d,
 g
eo
gr
ap
hi
c 
re
gi
on
, e
du
ca
tio
n,
 a
ge
 a
t m
en
ar
ch
e,
 B
M
I, 
m
en
op
au
sa
l s
ta
tu
s (
pre
-/p
os
t-)
, H
T 
us
e (
/ev
er
/n
ev
er
), p
ari
ty,
 
sm
o
ki
ng
 st
at
us
, a
nd
 d
ur
at
io
n 
of
 
o
ra
l c
on
tra
ce
pt
iv
e 
u
se
.
*
P-
tre
nd
 ex
cl
ud
es
 n
ev
er
 a
n
d 
pa
st 
dr
in
ke
rs
.
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Williams et al. Page 15
Ta
bl
e 
3
R
ec
en
t a
lc
oh
ol
 in
ta
ke
 a
n
d 
in
v
as
iv
e 
br
ea
st 
ca
nc
er
 b
y 
stu
dy
 fr
om
 th
e 
A
M
BE
R 
co
ns
or
tiu
m
C
on
tr
o
ls
N
 (%
)
C
as
es
N
 (%
)
Ba
sic
 m
od
el
a
O
R
 (9
5%
 C
I)
C
on
tr
o
ls
N
 (%
)
C
as
es
N
 (%
)
M
V
 m
od
el
b
O
R
 (9
5%
 C
I)
C
BC
S
N
um
be
r o
f a
lc
oh
ol
ic
 d
rin
ks
 p
er
 w
ee
k
 
N
ev
er
 d
rin
ke
rs
30
9 
(39
.4)
29
3 
(37
.5)
1.
16
 (0
.90
–1
.50
)
25
8 
(39
.0)
25
3 
(37
.5)
1.
23
 (0
.92
–1
.65
)
 
>
0–
<4
23
2 
(29
.6)
19
3 
(24
.7)
R
ef
.
19
9 
(30
.0)
16
6 
(24
.6)
R
ef
.
 
≥4
–<
7
44
 (5
.6)
32
 (4
.1)
0.
88
 (0
.53
–1
.43
)
36
 (5
.4)
28
 (4
.2)
0.
95
 (0
.55
–1
.64
)
 
≥7
54
 (6
.9)
88
 (1
1.3
)
2.
02
 (1
.37
–2
.99
)
46
 (6
.9)
72
 (1
0.7
)
2.
03
 (1
.29
–3
.18
)
 
Pa
st
 d
rin
ke
rs
14
5 
(18
.5)
75
 (2
2.4
)
1.
50
 (1
.11
–2
.03
)
12
3 
(18
.6)
15
5 
(23
.0)
1.
53
 (1
.09
–2
.14
)
 
p-
tre
nd
*
<
0.
01
0.
01
W
C
H
S
N
um
be
r o
f a
lc
oh
ol
ic
 d
rin
ks
 p
er
 w
ee
k
 
N
ev
er
 d
rin
ke
rs
79
1 
(65
.1)
79
8 
(65
.4)
0.
96
 (0
.72
–1
.27
)
74
2 
(66
.0)
72
7 
(65
.1)
0.
89
 (0
.66
–1
.21
)
 
>
0–
<4
11
1 
(9.
1)
11
3 
(9.
3)
R
ef
.
10
1 
(8.
9)
10
4 
(9.
3)
R
ef
.
 
≥4
–<
7
43
 (3
.5)
40
 (3
.3)
0.
91
 (0
.55
–1
.51
)
37
 (3
.3)
38
 (3
.4)
1.
01
 (0
.59
–1
.73
)
 
≥7
60
 (4
.9)
53
 (4
.3)
0.
84
 (0
.53
–1
.32
)
57
 (5
.1)
50
 (4
.5)
0.
81
 (0
.51
–1
.31
)
 
Pa
st
 d
rin
ke
rs
21
1 
(17
.4)
21
6 
(17
.7)
0.
96
 (0
.70
–1
.34
)
18
7 
(16
.6)
19
8 
(17
.7)
0.
98
 (0
.69
–1
.39
)
 
p-
tre
nd
*
0.
42
0.
40
M
EC
N
um
be
r o
f a
lc
oh
ol
ic
 d
rin
ks
 p
er
 w
ee
k
 
N
ev
er
 d
rin
ke
rs
2,
36
0 
(53
.3)
62
9 
(55
.5)
1.
07
 (0
.90
–1
.27
)
1,
90
8 
(51
.4)
47
8 
(53
.0)
1.
10
 (0
.91
–1
.34
)
 
>
0–
<4
90
6 
(20
.5)
22
6 
(19
.9)
R
ef
.
75
9 
(20
.5)
18
3 
(20
.3)
R
ef
.
 
≥4
–<
7
17
4 
(3.
9)
43
 (3
.8)
0.
99
 (0
.69
–1
.43
)
15
0 
(4.
0)
32
 (3
.6)
0.
92
 (0
.60
–1
.39
)
 
≥7
45
1 
(10
.2)
12
9 
(11
.4)
1.
15
 (0
.90
–1
.47
)
41
1 
(11
.8)
10
8 
(12
.0)
1.
06
 (0
.81
–1
.40
)
 
Pa
st
 d
rin
ke
rs
54
0 
(12
.2)
10
7 
(9.
4)
0.
79
 (0
.62
–1
.03
)
48
1 
(13
.0)
10
1 
(11
.2)
0.
87
 (0
.66
–1
.14
)
 
p-
tre
nd
*
0.
29
0.
63
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Williams et al. Page 16
C
on
tr
o
ls
N
 (%
)
C
as
es
N
 (%
)
Ba
sic
 m
od
el
a
O
R
 (9
5%
 C
I)
C
on
tr
o
ls
N
 (%
)
C
as
es
N
 (%
)
M
V
 m
od
el
b
O
R
 (9
5%
 C
I)
BW
H
S
N
um
be
r o
f a
lc
oh
ol
ic
 d
rin
ks
 p
er
 w
ee
k
 
N
ev
er
 d
rin
ke
rs
4,
05
6 
(37
.6)
79
7 
(40
.5)
1.
15
 (1
.02
–1
.30
)
3,
56
8 
(37
.9)
67
6 
(40
.8)
1.
17
 (1
.02
–1
.34
)
 
>
0–
<4
2,
86
5 
(26
.6)
49
1 
(24
.9)
R
ef
.
2,
48
0 
(26
.3)
40
9 
(24
.7)
R
ef
.
 
≥4
–<
7
61
5 
(5.
7)
10
8 
(5.
5)
1.
02
 (0
.82
–1
.28
)
52
7 
(5.
6)
94
 (5
.7)
1.
08
 (0
.85
–1
.38
)
 
≥7
48
6 
(4.
5)
98
 (5
.0)
1.
17
 (0
.92
–1
.49
)
41
4 
(4.
4)
78
 (4
.7)
1.
13
 (0
.87
–1
.48
)
 
Pa
st
 d
rin
ke
rs
2,
76
5 
(25
.6)
47
5 
(24
.1)
0.
99
 (0
.87
–1
.14
)
2,
43
3 
(25
.8)
39
9 
(24
.1)
1.
02
 (0
.88
–1
.19
)
 
p-
tre
nd
*
0.
23
0.
38
a B
as
ic
 m
od
el
 a
dju
ste
d f
or 
ag
e, 
stu
dy
,
 
tim
e 
pe
rio
d 
an
d 
ge
og
ra
ph
ic
 re
gi
on
.
b M
ul
tiv
ar
ia
bl
e 
m
od
el
 a
dju
ste
d f
or 
ag
e, 
stu
dy
,
 
tim
e 
pe
rio
d,
 g
eo
gr
ap
hi
c 
re
gi
on
, e
du
ca
tio
n,
 a
ge
 a
t m
en
ar
ch
e,
 B
M
I, 
m
en
op
au
sa
l s
ta
tu
s (
pre
-/p
os
t-)
, H
T 
us
e (
ev
er
/n
ev
er
), p
ari
ty,
 
sm
o
ki
ng
 st
at
us
, a
nd
 d
ur
at
io
n 
of
 
o
ra
l c
on
tra
ce
pt
iv
e 
u
se
*
p-
tre
nd
 ex
cl
ud
es
 n
ev
er
 a
n
d 
pa
st 
dr
in
ke
rs
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Williams et al. Page 17
Ta
bl
e 
4
Se
ns
iti
v
ity
 a
na
ly
sis
 to
 ex
am
in
e 
al
co
ho
l i
nt
ak
e 
(dr
ink
s p
er 
we
ek
) a
mo
ng
 ev
er
 d
rin
ke
rs
 d
ur
in
g 
di
ffe
re
nt
 a
ge
 p
er
io
ds
 p
rio
r t
o 
di
ag
no
sis
 in
 re
la
tio
n 
to
 in
v
as
iv
e 
br
ea
st 
ca
nc
er
 fo
r C
BC
S 
an
d 
W
CH
S
C
on
tr
o
ls
N
 (%
)
C
as
es
N
 (%
)
Ba
sic
 m
od
el
a
O
R
 (9
5%
 C
I)
C
on
tr
o
ls
N
 (%
)
C
as
es
N
 (%
)
M
V
 M
od
el
b
O
R
 (9
5%
 C
I)
Yo
u
n
g 
A
ge
 D
ri
nk
s p
er
 w
ee
k 
(<
30
 ye
a
rs
 o
ld
)*
N
um
be
r o
f a
lc
oh
ol
ic
 d
rin
ks
 p
er
 w
ee
k
 
0
1,
28
7 
(64
.3)
1,
29
5 
(64
.7)
1.
05
 (0
.90
–1
.23
)
1,
15
6 
(64
.7)
1,
15
9 
(64
.6)
1.
04
 (0
.88
–1
.23
)
 
>
0–
<4
46
3 
(23
.1)
43
9 
(21
.9)
R
ef
.
41
0 
(22
.9)
39
6 
(22
.1)
R
ef
.
 
≥4
–<
7
95
 (4
.8)
96
 (4
.8)
1.
06
 (0
.78
–1
.45
)
82
 (4
.6)
88
 (4
.9)
1.
09
 (0
.78
–1
.52
)
 
≥7
15
7 
(7.
8)
17
3 
(8.
6)
1.
16
 (0
.90
–1
.49
)
13
9 
(7.
8)
15
0 
(8.
4)
1.
07
 (0
.81
–1
.41
)
 
p-
tre
nd
0.
25
0.
64
M
id
dl
e 
ag
e 
D
ri
nk
s p
er
 w
ee
k 
(30
–
<
50
 y
ea
rs
 o
ld
)#
N
um
be
r o
f a
lc
oh
ol
ic
 d
rin
ks
 p
er
 w
ee
k
 
0
1,
26
5 
(63
.3)
1,
22
7 
(62
.1)
1.
01
 (0
.86
–1
.19
)
1,
14
0 
(64
.4)
1,
10
2 
(62
.4)
0.
97
 (0
.81
–1
.16
)
 
>
0–
<4
44
2 
(22
.3)
42
0 
(21
.3)
R
ef
.
38
3 
(21
.6)
36
9 
(20
.9)
R
ef
.
 
≥4
–<
7
10
9 
(5.
5)
13
2 
(6.
7)
1.
26
 (0
.95
–1
.68
)
92
 (5
.2)
12
4 
(7.
0)
1.
38
 (1
.01
–1
.88
)
 
≥7
17
6 
(8.
9)
19
7 
(10
.0)
1.
17
 (0
.92
–1
.49
)
15
5 
(8.
7)
17
1 
(9.
7)
1.
14
 (0
.87
–1
.49
)
 
p-
tre
nd
0.
12
0.
25
O
ld
er
 A
ge
 D
ri
nk
s p
er
 w
ee
k 
(50
+ y
ea
rs
 o
ld
)
N
um
be
r o
f a
lc
oh
ol
ic
 d
rin
ks
 p
er
 w
ee
k
 
0
87
9 
(78
.8)
90
6 
(80
.3)
1.
04
 (0
.81
–1
.34
)
77
0 
(78
.7)
78
6 
(79
.9)
1.
00
 (0
.75
–1
.32
)
 
>
0–
<4
14
5 
(13
.0)
14
1 
(12
.5)
R
ef
.
13
2 
(13
.4)
12
5 
(12
.6)
R
ef
.
 
≥4
–<
7
45
 (4
.0)
30
 (2
.7)
0.
70
 (0
.41
–1
.17
)
36
 (3
.7)
27
 (2
.7)
0.
76
 (0
.43
–1
.34
)
 
≥7
46
 (4
.1)
51
 (4
.5)
1.
08
 (0
.68
–1
.72
)
42
 (4
.3)
47
 (4
.7)
1.
07
 (0
.65
–1
.76
)
 
p-
tre
nd
0.
98
0.
94
R
es
tr
ic
te
d 
to
 W
o
m
en
 5
0+
 w
ith
 d
at
a 
fo
r 
a
ll 
ag
e 
pe
ri
od
s*
*
N
um
be
r o
f a
lc
oh
ol
ic
 d
rin
ks
 p
er
 w
ee
k
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Williams et al. Page 18
C
on
tr
o
ls
N
 (%
)
C
as
es
N
 (%
)
Ba
sic
 m
od
el
a
O
R
 (9
5%
 C
I)
C
on
tr
o
ls
N
 (%
)
C
as
es
N
 (%
)
M
V
 M
od
el
b
O
R
 (9
5%
 C
I)
 
0
87
5 
(78
.9)
89
3 
(80
.2)
1.
25
 (0
.92
–1
.69
)
76
7 
(78
.7)
77
4 
(79
.6)
1.
22
 (0
.87
–1
.71
)
 
>
0–
<4
14
5 
(13
.1)
14
0 
(12
.6)
R
ef
.
13
2 
(13
.5)
12
4 
(12
.8)
R
ef
.
 
≥4
–<
7
44
 (4
.0)
30
 (2
.7)
0.
63
 (0
.36
–1
.11
)
35
 (3
.6)
27
 (2
.8)
0.
68
 (0
.37
–1
.26
)
 
≥7
45
 (4
.1)
51
 (4
.6)
1.
14
 (0
.68
–1
.89
)
41
 (4
.2)
47
 (4
.8)
1.
14
 (0
.66
–1
.97
)
 
p-
tre
nd
0.
69
0.
65
a B
as
ic
 m
od
el
 a
dju
ste
d f
or 
ag
e, 
stu
dy
,
 
tim
e 
pe
rio
d 
an
d 
ge
og
ra
ph
ic
 re
gi
on
.
b M
ul
tiv
ar
ia
bl
e 
m
od
el
 a
dju
ste
d f
or 
ag
e, 
stu
dy
,
 
tim
e 
pe
rio
d,
 g
eo
gr
ap
hi
c 
re
gi
on
, e
du
ca
tio
n,
 a
ge
 a
t m
en
ar
ch
e,
 B
M
I, 
m
en
op
au
sa
l s
ta
tu
s (
pre
-/p
os
t-)
, H
T 
us
e (
ev
er
/n
ev
er
), p
ari
ty,
 
sm
o
ki
ng
 st
at
us
, a
nd
 d
ur
at
io
n 
of
 
o
ra
l c
on
tra
ce
pt
iv
e 
u
se
*
<
25
 y
ea
rs
 o
ld
 fo
r C
BC
S
# 2
5–
<5
0 
ye
ar
s o
ld
 fo
r C
BC
S
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2017 November 01.
